AbbVie Gains EU Approval For SKYRIZI To Treat Moderately To Severely Active Ulcerative Colitis In Adults
Portfolio Pulse from Benzinga Newsdesk
AbbVie has received EU approval for SKYRIZI to treat moderately to severely active ulcerative colitis in adults. This marks the fourth approved indication for SKYRIZI in the EU, supported by data from two pivotal Phase 3 trials.
July 26, 2024 | 6:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has received EU approval for SKYRIZI to treat moderately to severely active ulcerative colitis in adults. This approval, supported by successful Phase 3 trials, marks the fourth indication for SKYRIZI in the EU.
The EU approval for SKYRIZI to treat ulcerative colitis is a significant milestone for AbbVie, potentially boosting its revenue and market position. The approval is backed by successful Phase 3 trials, indicating strong efficacy and safety profiles.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100